Skip to main content

Maxalt-MLT Disease Interactions

There are 6 disease interactions with Maxalt-MLT (rizatriptan).

Major

5-HT1 agonists (applies to Maxalt-MLT) CAD risk factors

Major Potential Hazard, High plausibility. Applicable conditions: Hyperlipidemia, Smoking, Obesity, Diabetes Mellitus, History (Familial) - Ischemic Heart Disease, Menopausal Disorder

The group of drugs known as 5-hydroxytryptamine1 receptor (5-HT1) agonists can cause vasospastic reactions, including coronary vasospasm, peripheral vascular ischemia, and colonic ischemia. Rarely, serious adverse cardiac events including acute myocardial infarction, arrhythmia, cardiac arrest, and death have been reported within a few hours following the administration of 5-HT1 agonists, in some cases even in patients with no prior history or findings of coronary artery disease (CAD). Significant elevation in blood pressure, including hypertensive crisis, has also been reported on rare occasions in patients with and without a history of hypertension, as have transient increases in blood pressure and peripheral vascular resistance. In general, patients with potentially unrecognized CAD as predicted by the presence of risk factors (e.g., hypertension, hypercholesterolemia, tobacco use, obesity, diabetes, strong family history of CAD, female with surgical or physiological menopause, or male over 40 years of age) should not be administered 5-HT1 agonists unless a cardiovascular evaluation provides satisfactory clinical evidence indicating the lack of CAD, ischemic heart disease, or other significant underlying cardiovascular disease. As a precaution, the manufacturers recommend that the first dose be administered under medical surveillance in such patients, and that electrocardiographic monitoring be considered during the interval immediately following administration to help detect any asymptomatic cardiac ischemia that may occur. Periodic cardiovascular evaluations should be performed during intermittent, long-term use.

References

  1. Willett F, Curzen N, Adams J, Armitage M "Coronary vasospasm induced by subcutaneous sumatriptan." BMJ 304 (1992): 1415
  2. Ottervanger JP, van Witsen TB, Valkenburg HA, Stricker BH "Postmarketing study of cardiovascular adverse reactions associated with sumatriptan." BMJ 307 (1993): 1185
  3. Curtin T, Brooks AP, Roberts JA "Cardiorespiratory distress after sumatriptan given by injection." BMJ 305 (1992): d713-4
  4. Ottervanger JP, Paalman HJ, Boxma GL, Stricker BH "Transmural myocardial infarction with sumatriptan." Lancet 341 (1993): 861-2
  5. MacLean MR, Smith GC, Templeton AG "Adverse reactions associated with sumatriptan." Lancet 341 (1993): 1092
  6. Cavazos JE, Caress JB, Chilukuri VR, Devlin T, Gray L, Hurwitz BJ "Sumatriptan-induced stroke in sagittal sinus thrombosis." Lancet 343 (1994): 1105-6
  7. "Product Information. Imitrex (sumatriptan)." Glaxo Wellcome PROD (2001):
  8. Plosker GL, Mctavish D "Sumatriptan - a reappraisal of its pharmacology and therapeutic efficacy in the acute treatment of migraine and cluster headache." Drugs 47 (1994): 622-51
  9. Boyd IW, Rohan AP "Sumatriptan-induced chest pain." Lancet 344 (1994): 1704-5
  10. Ottervanger JP, Vanwitsen TB, Valkenburg HA, Grobbee DE, Stricker BHC "Adverse reactions attributed to sumatriptan - a postmarketing study in general practice." Eur J Clin Pharmacol 47 (1994): 305-9
  11. Kelly KM "Cardiac arrest following use of sumatriptan." Neurology 45 (1995): 1211-3
  12. Mueller L, Gallagher RM, Ciervo CA "Vasospasm-induced myocardial infarction with sumatriptan." Headache 36 (1996): 329-31
  13. Visser WH, Devriend RHM, Jaspers NMWH, Ferrari MD "Sumatriptan in clinical practice: a 2-year review of 453 migraine patients." Neurology 47 (1996): 46-51
  14. Visser WH, Jaspers NMWH, Devriend RHM, Ferrari MD "Chest symptoms after sumatriptan: a two-year clinical practice review in 735 consecutive migraine patients." Cephalalgia 16 (1996): 554-9
  15. "Product Information. Zomig (zolmitriptan)." Astra-Zeneca Pharmaceuticals PROD (2001):
  16. "Product Information. Amerge (naratriptan)." Glaxo Wellcome PROD (2001):
  17. "Product Information. Maxalt (rizatriptan)." Merck & Co., Inc PROD (2001):
  18. Dulli DA "Naratriptan: an alternative for migraine." Ann Pharmacotherapy 33 (1999): 704-11
  19. Dooley M, Faulds D "Rizatriptan - A review of its efficacy in the management of migraine." Drugs 58 (1999): 699-723
  20. Morgan DR, Trimble M, McVeigh GE "Atrial fibrillation associated with sumatriptan." Br Med J 321 (2000): 275
  21. "Product Information. Axert (almotriptan)." Pharmacia and Upjohn PROD (2001):
  22. "Product Information. Frova (frovatriptan)." Endo Laboratories LLC (2001):
  23. "Product Information. Relpax (eletriptan)." Pfizer U.S. Pharmaceuticals (2003):
View all 23 references
Major

5-HT1 agonists (applies to Maxalt-MLT) cardiovascular disease

Major Potential Hazard, High plausibility. Applicable conditions: History - Myocardial Infarction, Cerebral Vascular Disorder, History - Cerebrovascular Disease, Heart Disease

The use of 5-hydroxytryptamine receptor (5-HT1) agonists is contraindicated in patients with a history or current symptoms or signs of ischemic cardiac, cerebrovascular, and/or peripheral vascular diseases. In addition, these agents should not be used in patients with any other significant underlying cardiovascular disease or uncontrolled hypertension. 5-HT1 agonists can cause vasospastic reactions, including coronary vasospasm, peripheral vascular ischemia, and colonic ischemia. Some serious adverse cardiac events including acute myocardial infarction, arrhythmia, cardiac arrest, and death have been reported within a few hours following the administration of 5-HT1 agonists, in some cases even in patients with no prior history or findings of coronary artery disease (CAD). Significant elevation in blood pressure, including hypertensive crisis, has also been reported on rare occasions in patients with and without a history of hypertension, as have transient increases in blood pressure and peripheral vascular resistance. Cerebrovascular events have included cerebral hemorrhage, subarachnoid hemorrhage, and stroke, some resulting in fatalities. However, the relationship to 5-HT1 agonists is uncertain and, in a number of cases, the cerebrovascular events may have been primary where symptoms were mistaken to be migraine.

References

  1. Willett F, Curzen N, Adams J, Armitage M "Coronary vasospasm induced by subcutaneous sumatriptan." BMJ 304 (1992): 1415
  2. Ottervanger JP, van Witsen TB, Valkenburg HA, Stricker BH "Postmarketing study of cardiovascular adverse reactions associated with sumatriptan." BMJ 307 (1993): 1185
  3. Curtin T, Brooks AP, Roberts JA "Cardiorespiratory distress after sumatriptan given by injection." BMJ 305 (1992): d713-4
  4. Ottervanger JP, Paalman HJ, Boxma GL, Stricker BH "Transmural myocardial infarction with sumatriptan." Lancet 341 (1993): 861-2
  5. MacLean MR, Smith GC, Templeton AG "Adverse reactions associated with sumatriptan." Lancet 341 (1993): 1092
  6. Cavazos JE, Caress JB, Chilukuri VR, Devlin T, Gray L, Hurwitz BJ "Sumatriptan-induced stroke in sagittal sinus thrombosis." Lancet 343 (1994): 1105-6
  7. "Product Information. Imitrex (sumatriptan)." Glaxo Wellcome PROD (2001):
  8. Plosker GL, Mctavish D "Sumatriptan - a reappraisal of its pharmacology and therapeutic efficacy in the acute treatment of migraine and cluster headache." Drugs 47 (1994): 622-51
  9. Boyd IW, Rohan AP "Sumatriptan-induced chest pain." Lancet 344 (1994): 1704-5
  10. Ottervanger JP, Vanwitsen TB, Valkenburg HA, Grobbee DE, Stricker BHC "Adverse reactions attributed to sumatriptan - a postmarketing study in general practice." Eur J Clin Pharmacol 47 (1994): 305-9
  11. Kelly KM "Cardiac arrest following use of sumatriptan." Neurology 45 (1995): 1211-3
  12. Mueller L, Gallagher RM, Ciervo CA "Vasospasm-induced myocardial infarction with sumatriptan." Headache 36 (1996): 329-31
  13. Visser WH, Devriend RHM, Jaspers NMWH, Ferrari MD "Sumatriptan in clinical practice: a 2-year review of 453 migraine patients." Neurology 47 (1996): 46-51
  14. Visser WH, Jaspers NMWH, Devriend RHM, Ferrari MD "Chest symptoms after sumatriptan: a two-year clinical practice review in 735 consecutive migraine patients." Cephalalgia 16 (1996): 554-9
  15. "Product Information. Zomig (zolmitriptan)." Astra-Zeneca Pharmaceuticals PROD (2001):
  16. "Product Information. Amerge (naratriptan)." Glaxo Wellcome PROD (2001):
  17. "Product Information. Maxalt (rizatriptan)." Merck & Co., Inc PROD (2001):
  18. Dulli DA "Naratriptan: an alternative for migraine." Ann Pharmacotherapy 33 (1999): 704-11
  19. Dooley M, Faulds D "Rizatriptan - A review of its efficacy in the management of migraine." Drugs 58 (1999): 699-723
  20. Morgan DR, Trimble M, McVeigh GE "Atrial fibrillation associated with sumatriptan." Br Med J 321 (2000): 275
  21. "Product Information. Axert (almotriptan)." Pharmacia and Upjohn PROD (2001):
  22. "Product Information. Frova (frovatriptan)." Endo Laboratories LLC (2001):
  23. "Product Information. Relpax (eletriptan)." Pfizer U.S. Pharmaceuticals (2003):
View all 23 references
Major

Rizatriptan (applies to Maxalt-MLT) liver disease

Major Potential Hazard, High plausibility.

Rizatriptan is primarily metabolized by the liver. Following oral administration in patients with alcoholic cirrhosis of the liver, the plasma concentrations of rizatriptan were not significantly altered in patients with mild hepatic impairment but were approximately 30% higher in patients with moderate hepatic impairment compared to healthy controls. Therapy with rizatriptan should be administered cautiously in patients with significantly impaired hepatic function. A lower initial dosage may be appropriate.

References

  1. "Product Information. Maxalt (rizatriptan)." Merck & Co., Inc PROD (2001):
Major

Rizatriptan (applies to Maxalt-MLT) migraines

Major Potential Hazard, Moderate plausibility.

The use of rizatriptan is contraindicated in patients with hemiplegic or basilar migraine.

References

  1. "Product Information. Maxalt (rizatriptan)." Merck & Co., Inc PROD (2001):
Moderate

Rizatriptan (applies to Maxalt-MLT) PKU

Moderate Potential Hazard, High plausibility. Applicable conditions: Phenylketonuria

Maxalt-MLT (brand of rizatriptan) orally disintegrating tablets contain 1.05 mg and 2.10 mg of phenylalanine per each 5 mg and 10 mg tablet, respectively. The phenylalanine content should be considered when these products are used in patients who must restrict their intake of phenylalanine (i.e. phenylketonurics).

References

  1. "Product Information. Maxalt (rizatriptan)." Merck & Co., Inc PROD (2001):
Moderate

Rizatriptan (applies to Maxalt-MLT) renal dysfunction

Moderate Potential Hazard, High plausibility.

Rizatriptan is excreted in the urine primarily as metabolites but also as unchanged drug. Following oral administration in patients with renal impairment (CrCl = 10 to 60 mL/min/1.73 m2), the plasma concentrations of rizatriptan were not significantly altered compared to healthy controls. In hemodialysis patients (CrCl < 2 mL/min/1.73 m2), however, the area under the plasma concentration-time curve (AUC) was approximately 44% greater than that in controls. Therapy with rizatriptan should be administered cautiously in dialysis patients and patients with significantly impaired renal function. A lower initial dosage may be appropriate.

References

  1. "Product Information. Maxalt (rizatriptan)." Merck & Co., Inc PROD (2001):

Maxalt-MLT drug interactions

There are 92 drug interactions with Maxalt-MLT (rizatriptan).

Maxalt-MLT alcohol/food interactions

There are 2 alcohol/food interactions with Maxalt-MLT (rizatriptan).


Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.